EP2994162A4 - Vaccin pour pcv2 et mycoplasme - Google Patents

Vaccin pour pcv2 et mycoplasme

Info

Publication number
EP2994162A4
EP2994162A4 EP14794866.5A EP14794866A EP2994162A4 EP 2994162 A4 EP2994162 A4 EP 2994162A4 EP 14794866 A EP14794866 A EP 14794866A EP 2994162 A4 EP2994162 A4 EP 2994162A4
Authority
EP
European Patent Office
Prior art keywords
pcv2
mycoplasma
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP14794866.5A
Other languages
German (de)
English (en)
Other versions
EP2994162A1 (fr
EP2994162B1 (fr
Inventor
Shi Jun Ma
Jing Sui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmgate Biologics Inc
Original Assignee
Protatek International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51867734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2994162(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Protatek International Inc filed Critical Protatek International Inc
Priority to PL14794866T priority Critical patent/PL2994162T3/pl
Publication of EP2994162A1 publication Critical patent/EP2994162A1/fr
Publication of EP2994162A4 publication Critical patent/EP2994162A4/fr
Application granted granted Critical
Publication of EP2994162B1 publication Critical patent/EP2994162B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP14794866.5A 2013-05-08 2014-05-08 Vaccin pour pcv2 et mycoplasme Active EP2994162B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL14794866T PL2994162T3 (pl) 2013-05-08 2014-05-08 Szczepionka przeciwko pcv2 i mykoplazmie

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361821011P 2013-05-08 2013-05-08
PCT/US2014/037246 WO2014182872A1 (fr) 2013-05-08 2014-05-08 Vaccin pour pcv2 et mycoplasme

Publications (3)

Publication Number Publication Date
EP2994162A1 EP2994162A1 (fr) 2016-03-16
EP2994162A4 true EP2994162A4 (fr) 2016-12-21
EP2994162B1 EP2994162B1 (fr) 2021-04-07

Family

ID=51867734

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14794866.5A Active EP2994162B1 (fr) 2013-05-08 2014-05-08 Vaccin pour pcv2 et mycoplasme

Country Status (6)

Country Link
US (2) US9649370B2 (fr)
EP (1) EP2994162B1 (fr)
DK (1) DK2994162T3 (fr)
ES (1) ES2882374T3 (fr)
PL (1) PL2994162T3 (fr)
WO (1) WO2014182872A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014182872A1 (fr) * 2013-05-08 2014-11-13 Protatek International, Inc. Vaccin pour pcv2 et mycoplasme
WO2016091998A1 (fr) 2014-12-11 2016-06-16 Intervet International B.V. Procédé pour un vaccin associé prêt à l'emploi pcv2 / m. hyo
US11744883B2 (en) 2017-12-22 2023-09-05 Hipra Scientific, S.L.U. Intradermal combination vaccine against mycoplasma and porcine circovirus
CN110045117A (zh) * 2019-05-06 2019-07-23 江苏南农高科技股份有限公司 猪肺炎支原体固相竞争elisa试剂盒及其制备方法和应用
WO2021018806A1 (fr) * 2019-07-26 2021-02-04 Ceva Sante Animale Sérum porcin appauvri en igg et ses utilisations
CN112213484A (zh) * 2020-12-10 2021-01-12 北京科牧丰生物制药有限公司 一种基于elisa法检验猪肺炎支原体灭活疫苗体外效力的方法
CN114134098A (zh) * 2021-12-15 2022-03-04 成都史纪生物制药有限公司 一种猪肺炎支原体的灭活方法
CN114470181B (zh) * 2022-02-21 2024-01-09 成都依思康生物科技有限公司 一种猪圆环病毒2型（pcv2）的复合水佐剂疫苗及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017210A1 (fr) * 1993-12-23 1995-06-29 Smithkline Beecham Biologicals (S.A.) Vaccins
US5733555A (en) * 1994-05-10 1998-03-31 American Home Products Corporation Modified live BRSV vaccine
WO2003005952A2 (fr) * 2001-07-10 2003-01-23 Corixa Corporation Compositions et procedes destines a l'administration de proteines et d'adjuvants encapsules dans des microspheres

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0571648A1 (fr) 1992-05-26 1993-12-01 Chung-Nan Weng Vaccin protégeant contre la pneumonie mycoplasmique
AUPN178995A0 (en) * 1995-03-16 1995-04-13 University Of Melbourne, The Antigen composition
BR9803232A (pt) 1997-08-26 2000-01-11 Pfizer Prod Inc Vaicna de neospora.
US6391314B1 (en) 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
FR2781159B1 (fr) 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
UA78180C2 (uk) 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
US6224882B1 (en) 1997-11-07 2001-05-01 Protein Science Corp. Insect cells or fractions as adjuvant for antigens
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
FR2789695B1 (fr) 1999-02-11 2003-03-07 Merial Sas Vecteurs et vaccins viraux a base d'adenovirus porcins recombines et replicatifs
US6497883B1 (en) 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
US6943152B1 (en) 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
US7018638B2 (en) 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
RU2354399C2 (ru) 2003-07-24 2009-05-10 Мериал Лимитед Вакцинная композиция и способ индуцирования иммунологического ответа у животного
HUE028343T2 (en) 2005-04-13 2016-12-28 Merial Inc Method for the production of porcine circovirus
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
BRPI0615862A2 (pt) 2005-09-09 2011-05-31 Intervet Int Bv vacina contra pcv-2, e, método para a manufatura de uma vacina
HUE051025T2 (hu) 2005-12-29 2021-01-28 Boehringer Ingelheim Animal Health Usa Inc Multivalens PCV2 immunogén készítmények és eljárások ilyen készítmények elõállítására
CL2007003648A1 (es) 2006-12-15 2008-04-11 Boehringer Ingelheim Vetmed Metodo para el tratamiento o profilaxis de infeccion por circovirus 2 porcino (pcv2) o para la reduccion de los sintomas clinicos asociados a pcv2 en animales que tienen anticuerpos anti-pcv2 y/o que tienen 1 a 22 dias de edad que comprende administr
EP1958644A1 (fr) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prévention et traitement du PCVD subclinique
US9056909B2 (en) 2007-11-06 2015-06-16 Zoetis Services Llc Mycoplasma hyopneumoniae avirulent adjuvanted live vaccine
UA99495C2 (ru) 2007-12-21 2012-08-27 Вайет Ллк Изольованный цирковирус свиней, композиции и способы для иммунизации свиней против цирковируса свиней
BRPI0907438A2 (pt) 2008-01-23 2015-08-04 Boehringer Ingelheim Vetmed Composições imunogênicas para mycoplasma hyopneumoniae e pcv2 e métodos para produzir tais composições
WO2010044889A2 (fr) 2008-10-16 2010-04-22 Pfizer Inc. Isolats de torque teno virus (ttv) et compositions associées
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
NZ598645A (en) 2009-09-10 2014-07-25 Merial Ltd New vaccine formulations comprising saponin-containing adjuvants
TWI508974B (zh) 2010-12-22 2015-11-21 Sbc Virbac Ltd 豬第二型環狀病毒(Porcine Circovirus Type 2)、含彼之免疫組合物、檢測套組及其應用
UA113192C2 (xx) 2011-12-06 2016-12-26 Імуногенна композиція проти цирковірусу свиней типу 2 (pcv2)
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
EP2684959A1 (fr) 2012-07-10 2014-01-15 Laboratorios Hipra, S.A. Vecteurs pour la transformation de Mycoplasma hyopneumoniae, souches transformantes de M.hyopneumoniae, et leur utilisation.
WO2014182872A1 (fr) 2013-05-08 2014-11-13 Protatek International, Inc. Vaccin pour pcv2 et mycoplasme
KR102319843B1 (ko) 2013-09-25 2021-10-29 조에티스 서비시즈 엘엘씨 Pcv2b 분지형 백신 조성물 및 사용 방법
EP3098301B1 (fr) 2014-01-26 2020-06-10 Jiangsu Academy of Agricultural Sciences Vaccin vivant atténué contre la pneumonie enzootique du porc, et son utilisation
WO2016091998A1 (fr) 2014-12-11 2016-06-16 Intervet International B.V. Procédé pour un vaccin associé prêt à l'emploi pcv2 / m. hyo

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017210A1 (fr) * 1993-12-23 1995-06-29 Smithkline Beecham Biologicals (S.A.) Vaccins
US5733555A (en) * 1994-05-10 1998-03-31 American Home Products Corporation Modified live BRSV vaccine
WO2003005952A2 (fr) * 2001-07-10 2003-01-23 Corixa Corporation Compositions et procedes destines a l'administration de proteines et d'adjuvants encapsules dans des microspheres

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ALEX EGGEN ET AL: "Combining Mycoplasma hyopneumoniae and Porcine Circovirus Type 2, a research report", 1 January 2011 (2011-01-01), Proceedings of the 5th Asian Pig Veterinary Society Congress7-9 March 2011, Pattaya, Thailand, XP055258982, Retrieved from the Internet <URL:http://www.vet.chula.ac.th/vet2014/Ebook/ebook/APVS2011/context/papers/poster/P109.pdf> [retrieved on 20161103] *
ALVARO RUIZ ET AL: "Porcine Circovirus Associated Diseases (PCVAD) - Control - Clinical and pathologic lesions after simultaneous vaccination with PCV2 and Mycoplasma vaccine in 3 week old piglets", no. Poster P.132, 21 July 2010 (2010-07-21), Proceedings of the 21st IPVS Congress, Vancouver, Canada - July 18-21, 2010, XP055259199, Retrieved from the Internet <URL:http://orbit.dtu.dk/fedora/objects/orbit:63423/datastreams/file_5574380/content> [retrieved on 20160317] *
EGGEN A A ET AL: "One-dose vaccination against Mycoplasma hyopneumoniae and porcine circovirus type 2", PROCEEDINGS OF THE 21ST INTERNATIONAL PIG VETERINARY SOCIETY (IPVS) CONGRESS 2010 ; 19-21 JULY, 2010; VANCOUVER, CANADA,, 19 July 2010 (2010-07-19), pages 110, XP002740787 *
FARRERES J ET AL: "Serology and safety of the simultaneous use of Porcilis PCV and M+PAC in the field", PROCEEDINGS OF THE 21ST IPVS CONGRESS, VANCOUVER, CANADA - JULY 18-21, 2010. 1036. POSTER PRESENTATIONS,, 18 July 2010 (2010-07-18), pages 408, XP002740786 *
HERBICH E ET AL: "[Field trial on the simultaneous vaccination against porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae].", 1 May 2013 (2013-05-01), XP002763787, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pubmed/24126996> [retrieved on 20161103] *
RIVERA E ET AL: "Ginseng and aluminium hydroxide act synergistically as vaccine adjuvants", VACCINE, vol. 21, no. 11-12, 7 March 2003 (2003-03-07), ELSEVIER LTD, GB, pages 1149 - 1157, XP004404291, ISSN: 0264-410X, DOI: 10.1016/S0264-410X(02)00518-2 *
See also references of WO2014182872A1 *
SUN H X ET AL: "Advances in saponin-based adjuvants", VACCINE, vol. 27, no. 12, 13 March 2009 (2009-03-13), ELSEVIER LTD, GB, pages 1787 - 1796, XP026002489, ISSN: 0264-410X, [retrieved on 20090207], DOI: 10.1016/J.VACCINE.2009.01.091 *

Also Published As

Publication number Publication date
US20170216424A1 (en) 2017-08-03
ES2882374T3 (es) 2021-12-01
DK2994162T3 (en) 2021-06-21
EP2994162A1 (fr) 2016-03-16
US20160082095A1 (en) 2016-03-24
PL2994162T3 (pl) 2021-10-18
US9649370B2 (en) 2017-05-16
WO2014182872A1 (fr) 2014-11-13
US9956279B2 (en) 2018-05-01
EP2994162B1 (fr) 2021-04-07

Similar Documents

Publication Publication Date Title
IL276210A (en) MERS-COV vaccine
IL279395A (en) A vaccine
HK1226440A1 (zh) Cmv疫苗
HK1207284A1 (en) Mycoplasma hyopneumoniae vaccine
HRP20181376T1 (hr) Poboljšana cjepiva protiv poksvirusa
PL2994162T3 (pl) Szczepionka przeciwko pcv2 i mykoplazmie
GB201315946D0 (en) Oncology vaccine
AP2015008926A0 (en) Malaria vaccine
GB201301085D0 (en) Glycoconjugate Vaccine
DK2976355T3 (en) Vaccines against chlamydia sp
EP3022298A4 (fr) Vaccins atténués contre la grippe et leurs utilisations
HK1217206A1 (zh) 疫苗
GB2547494B (en) Monovalent H5 vaccine
EP2968557A4 (fr) Amélioration de vaccins
TWM476905U (en) Hot air device
GB201320646D0 (en) Vaccine
GB201315556D0 (en) Vaccine
GB201319209D0 (en) Sterilisation device
GB201310136D0 (en) Multivalent and monovalent vaccines
GB201320421D0 (en) Conjugated vaccine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20151125

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/12 20060101ALI20161109BHEP

Ipc: A61K 39/02 20060101ALI20161109BHEP

Ipc: A61K 39/295 20060101AFI20161109BHEP

Ipc: A61K 39/00 20060101ALI20161109BHEP

Ipc: C12N 7/00 20060101ALI20161109BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20161123

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/12 20060101ALI20161116BHEP

Ipc: A61K 39/02 20060101ALI20161116BHEP

Ipc: A61K 39/295 20060101AFI20161116BHEP

Ipc: C12N 7/00 20060101ALI20161116BHEP

Ipc: A61K 39/00 20060101ALI20161116BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20190509

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PHARMGATE BIOLOGICS INC.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/295 20060101AFI20200629BHEP

Ipc: C12N 7/00 20060101ALI20200629BHEP

Ipc: A61K 39/12 20060101ALI20200629BHEP

Ipc: A61P 31/04 20060101ALI20200629BHEP

Ipc: A61K 39/02 20060101ALI20200629BHEP

Ipc: A61K 39/00 20060101ALI20200629BHEP

INTG Intention to grant announced

Effective date: 20200727

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

INTC Intention to grant announced (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20201029

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1378813

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210415

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602014076402

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20210614

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20210407

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1378813

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210407

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210407

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210707

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210407

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210407

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210407

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210407

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210407

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210708

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210807

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210407

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210407

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210707

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210809

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2882374

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20211201

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DE

Ref legal event code: R026

Ref document number: 602014076402

Country of ref document: DE

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210407

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210407

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210407

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210407

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210407

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210531

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210508

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210407

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210531

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20210531

26 Opposition filed

Opponent name: BOEHRINGER INGELHEIM VETMEDICA GMBH

Effective date: 20220107

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20210707

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210508

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210707

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210807

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210407

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210407

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210531

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20140508

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20230322

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210407

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230412

Year of fee payment: 10

Ref country code: ES

Payment date: 20230608

Year of fee payment: 10

Ref country code: DK

Payment date: 20230426

Year of fee payment: 10

Ref country code: DE

Payment date: 20230412

Year of fee payment: 10

PLAY Examination report in opposition despatched + time limit

Free format text: ORIGINAL CODE: EPIDOSNORE2

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210407